Opinion of the Transparency Council – rituximab

At its meeting on 29 July 2024, the Transparency Council adopted opinion No. 114/2024 on the inclusion in the reimbursement of medicines containing the active substance rituximab for the off-label indication: indicated in the application, in the framework of the B.75 drug programme

Publication on the list of opinions on active substances for off-label indications >>